Mesa Laboratories (FRA:MLI) ROCE % : 2.33% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Mesa Laboratories ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Mesa Laboratories's annualized ROCE % for the quarter that ended in Dec. 2023 was 2.33%.

Mesa Laboratories ROCE % Historical Data

The historical data trend for Mesa Laboratories's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesa Laboratories ROCE % Chart

Mesa Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

7.75

3.65

2.10

1.26

0.70

Mesa Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															1.93	0.71	0.07	-0.28	2.33

Mesa Laboratories ROCE % Calculation

Mesa Laboratories's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	4.092	/	( ( (642.291 - 43.634)	+	(618.151 - 40.497) )	/ 2 )
	=	4.092	/	( (598.657	+	577.654)	/ 2 )
	=	4.092	/	588.1555
	=	0.70 %

Mesa Laboratories's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	13.944	/	( ( (597.045 - 37.308)	+	(680.202 - 40.516) )	/ 2 )
	=	13.944	/	( ( 559.737	+	639.686 )	/ 2 )
	=	13.944	/	599.7115
	=	2.33 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Mesa Laboratories (FRA:MLI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Mesa Laboratories ROCE % Related Terms

Thank you for viewing the detailed overview of Mesa Laboratories's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesa Laboratories (FRA:MLI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Hardware » Mesa Laboratories Inc (FRA:MLI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MLAB:USA

Address

12100 West Sixth Avenue, Lakewood, CO, USA, 80228

Website

https://www.mesalabs.com

Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, cleaning, and chemical indicators. It also provides testing and laboratory services, mainly to the dental industry; Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions; Calibration Solutions division develops, manufactures, and sells quality control and calibration products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters for health and safety purposes; and Clinical Genomics. Its geographical segments include United States and Foreign.